Clinical and molecular characteristics of Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma (NHL) is a diverse group of lymphoid cencers that affect the immune system. It is one of the most common types of cancer, with thousands of new cases diagnosed each year. Understanding both clinical and molecular characteristics of NHL is crucial for accurate diagnosis, prognosis (predicting the likely outcome), and choosing the best treatment options. Molecular characteristics include genetic changes identified through specialized tests, like next generation sequencing, performed on tumor tissue or blood samples. Clinical features such as age, gender, disease stage, and performance status (how well a patient can perform daily tasks) have been traditionally used to guide treatment decisions. However, recent advancements in research emphasize the value of combining clinical and molecular data to improve patient care.

This study aims to identify new clinical and molecular characteristics that influence lymphoma outcomes. We will analyze each variable individually to assess its association with progression-free survival (PFS)—the length of time during and after treatment before disease progression—and overall survival (OS)—the percentage of patients alive after a set period, such as five years.

By combining multiple types of data, this research has the potential to uncover previously unrecognized patterns and connections. Identifying and validating new factors could help clinicians better predict disease progression and tailor treatment strategies for individual patients. Ultimately, this may lead to improved patient outcomes and more cost-effective healthcare.